<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2014-5-160-168</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-235</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW AND LECTURES</subject></subj-group></article-categories><title-group><article-title>СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О БИЛАТЕРАЛЬНОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ</article-title><trans-title-group xml:lang="en"><trans-title>MODERN VIEWS ON BILATERAL BREAST CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фесик</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fesik</surname><given-names>Ye. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фесик Евгения Анатольевна — очный аспирант кафедры патологической анатомии СибГМУ, врач-патологоанатом отделения патологической анатомии и цитологии НИИ онкологии СО РАМН</p></bio><bio xml:lang="en"/><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крахмаль</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Krakhmal</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Крахмаль Надежда Валерьевна — очный аспирант кафедры патологической анатомии, ассистент кафедры патологической анатомии</p></bio><bio xml:lang="en"/><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Завьялова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zavyalova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Завьялова Марина Викторовна — доктор медицинских наук, профессор, зав. кафедрой патологической анатомии СибГМУ, старший научный сотрудник отделения патологической анатомии и цитологии НИИ онкологии СО РАМН</p></bio><bio xml:lang="en"/><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перельмутер</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Perelmuter</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Перельмутер Владимир Михайлович — доктор медицинских наук, профессор, руководитель отделения патологической анатомии и цитологии НИИ онкологии СО РАМН, профессор кафедры патологической анатомии СибГМУ</p></bio><bio xml:lang="en"/><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слонимская</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Slonimskaya</surname><given-names>Ye. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Слонимская Елена Михайловна — доктор медицинских наук, профессор, руководитель отделения общей онкологии НИИ онкологии СО РАМН, профессор кафедры онкологии СибГМУ</p></bio><bio xml:lang="en"/><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вторушин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vtorushin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вторушин Сергей Владимирович — доктор медицинских наук, доцент, профессор кафедры патологической анатомии СибГМУ, старший научный сотрудник отделения патологической анатомии и цитологии НИИ онкологии СО РАМН</p></bio><bio xml:lang="en"/><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет; НИИ онкологии СО РАМН, Томск</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University; &#13;
Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет, Томск</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University, Tomsk</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2014</year></pub-date><volume>13</volume><issue>5</issue><fpage>160</fpage><lpage>168</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фесик Е.А., Крахмаль Н.В., Завьялова М.В., Перельмутер В.М., Слонимская Е.М., Вторушин С.В., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Фесик Е.А., Крахмаль Н.В., Завьялова М.В., Перельмутер В.М., Слонимская Е.М., Вторушин С.В.</copyright-holder><copyright-holder xml:lang="en">Fesik Y.A., Krakhmal N.V., Zavyalova M.V., Perelmuter V.M., Slonimskaya Y.M., Vtorushin S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/235">https://bulletin.ssmu.ru/jour/article/view/235</self-uri><abstract><p>Представлены современные литературные данные, касающиеся особенностей патогенеза, течения, клинико-морфологических и экспрессионных характеристик опухоли, параметров лимфогенного и гематогенного метастазирования при билатеральном раке молочной железы (РМЖ). Освещены результаты отечественных и зарубежных исследований последних лет на предмет определения факторов прогноза и рецидивирования при синхронном и метахронном двухстороннем РМЖ. Выявлено, что частота встречаемости двухстороннего опухолевого поражения молочных желез варьирует в широких пределах и составляет от 0,1 до 20%, при этом метахронные опухоли регистрируются достоверно чаще (69,6%), чем синхронные (22,7%). Вероятность возникновения метахронного РМЖ выше у женщин с отягощенным семейным анамнезом, а также при наличии у них мутации гена BRCA1. Установлено, что наиболее распространенным гистологическим типом опухоли молочной железы при двухстороннем поражении является инвазивная протоковая карцинома. Однако заболеваемость инвазивным и неинвазивным дольковым раком несколько выше среди синхронного двухстороннего рака в сравнении с односторонним поражением. Исследования показали, что при синхронном двухстороннем РМЖ опухоль, как правило, имеет более низкую степень дифференцировки и более высокий уровень экспрессии рецепторов эстрогена и прогестерона. Актуальность вопроса заключается в том, что выявление закономерностей при изучении особенностей лимфогенного и гематогенного метастазирования билатеральных опухолей молочных желез дает основу для предположений о различиях в прогрессии опухолевой болезни в данных группах и является поводом для дальнейших детальных исследований в этой области с целью определения и оценки прогноза, а также выбора тактики ведения таких больных.</p></abstract><trans-abstract xml:lang="en"><p>Presented modern literature data on the features of the pathogenesis, course, clinical and morphological expression and tumor characteristics, parameters and nodal metastasis of hematogenous bilateral breast cancer. Highlight the results of domestic and foreign studies in recent years to determine the prognostic factors and recurrence of synchronous and metachronous bilateral breast cancer. It was revealed that the frequency of bilateral breast tumor lesions varies widely, ranging from 0.1 to 20%, with metachronous tumors recorded significantly higher (69.6% ) than the synchronous (22.7%). The probability of occurrence of metachronous breast cancer is higher in women with a family history, as well as if they have a gene mutation BRCA-1. Found that the most common histological type of breast tumor with bilateral lesions is invasive ductal. However, the incidence of invasive lobular cancer and non-invasive lobular cancer is slightly higher among synchronous bilateral cancer compared with unilateral disease. Studies have shown that in a double-sided synchronous breast cancer tumor, as a rule, has a lower degree of differentiation, and the higher the expression level of estrogen receptors and progesterone receptors. Relevance of the issue because the identification of patterns in the study of lymphatic and hematogenous features bilateral metastasis of mammary tumors provides a basis for speculation about the differences in the progression of neoplastic disease in these groups and is a cause for further detailed research in this area to identify and evaluate the prognosis and also the choice of tactics of such patients.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>билатеральный рак молочной железы</kwd><kwd>особенности течения</kwd><kwd>морфология</kwd><kwd>прогноз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bilateral breast cancer</kwd><kwd>especially flow</kwd><kwd>morphology</kwd><kwd>prognosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Российский научный фонд</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Давыдов М.И., Аксель Е.М. Вестник РОНЦ им. Н. Н. Бло¬хина РАМН. 2006. Т. 17, № 3. Прил. 1. С. 47, 82, 108, 113.</mixed-citation><mixed-citation xml:lang="en">Davydov M.I., Aksel' E.M. Vestnik RONTs im. N.N. Blokhina RAMN, 2006, vol. 17, no. 3. Prilozhenie 1, pp. 47, 82, 108, 113 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Стенина М.Б. Рак молочной железы: некоторые важные научные события и выводы последних лет // Практическая онкология. 2005. № 1. С. 26–32.</mixed-citation><mixed-citation xml:lang="en">Stenina M.B. Practical Oncology, 2005, no. 1, pp. 26–32 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Carlson R.W., Allred D.C., Anderson B.O. et al. Breast cancer. Clinical practice guidelines in oncology // JNCCN. 2009. V. 7 (2). Р. 122–192.</mixed-citation><mixed-citation xml:lang="en">Carlson, R.W., Allred D.C., Anderson B.O. et al. Breast cancer. Clinical practice guidelines in oncology. JNCCN, 2009, vol. 7 (2), pp. 122–192.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Керимов Р.А. Двусторонний рак молочных желез: особенности течения и результаты терапии // Маммология. 2005. № 1. C. 36–41.</mixed-citation><mixed-citation xml:lang="en">Kerimov R.A. Mammologiya, 2005, no. 1, pp. 36–41 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Biesheuvel S., Weigel S., Heindel W. Mammography Screening: Evidence, History and Current Practice in Ger-many and Other European Countries // Breast care (Basel, Switzerland). 2011. V. 6 (2). Р. 104–109.</mixed-citation><mixed-citation xml:lang="en">Biesheuvel S., Weigel S., Heindel W. Mammography Screening: Evidence, History and Current Practice in Ger-many and Other European Countries. Breast care (Basel, Switzerland), 2011, vol. 6 (2), pp. 104–109.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Steven A. Narod Bilateral breast cancer // Nature Reviews Clinical Oncology. 2014. V. 11, pp. 157–166.</mixed-citation><mixed-citation xml:lang="en">Steven A. Narod Bilateral breast cancer. Nature Reviews Clinical Oncology, 2014, vol. 11, pp. 157–166.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Чиссов В.И., Старинский В.В., Данилова Т.В. К проблеме профилактики онкологических заболеваний у женщин трудоспособного возраста // Материалы Всерос. науч.-практ. конф. «Онкологическая служба в условиях реформирования здравоохранения Российской Федерации». Казань, 2005. С. 256–261.</mixed-citation><mixed-citation xml:lang="en">Chissov V.I., Starinskiy V.V., Danilova T.V. On the prob-lem of prevention of cancer among women of working age. Proceedings of the All-Russian scientific and practical conference “Oncological service in terms of health care reform of the Russian Federation”. Kazan, 2005, pp. 256–261 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Чиссов В.И., Старинский В.В., ПетроваВ. и др. Анализ состояния онкологической помощи населению Рос-сии в 2004 году // Материалы Всерос. науч.-практ. конф. «Онкологическая служба в условиях реформирования здравоохранения Российской Федерации». Казань, 2005. С. 266–271.</mixed-citation><mixed-citation xml:lang="en">Chissov V.I., Starinskiy V.V., Danilova T.V. et al. Analysis of the state of cancer care in Russia in 2004. Proceedings of the All-Russian scientific and practical conference “Oncological service in terms of health care reform of the Russian Federation”. Kazan, 2005, pp. 266–271 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Deo V.S., Shridhar D., Shukla N.K. et al. Clinical profile and management of bilateral breast cancer // Breast Cancer Research. 2005. V. 7. Suppl. 1, pp. 6–10.</mixed-citation><mixed-citation xml:lang="en">Deo V.S., Shridhar D., Shukla N.K. et al. Clinical profile and management of bilateral breast cancer. Breast Cancer Research, 2005, vol. 7. Suppl. 1, pp. 6–10.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Филюшкин И.Ю., Иванов В.М., Буйденок Ю.М. Синхронный рак молочных желез: клиника, диагностика, лечение, прогноз // Опухоли женской репродуктивной системы. 2007. № 4. С. 14–16.</mixed-citation><mixed-citation xml:lang="en">Filyushkin I. Yu., Ivanov V.M, Buydenok Yu.M. Tumors of the Female Reproductive System, 2007, no. 4, pp. 14–16 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Селезнева Т.Д. Ошибки в диагностике первично-множественных синхронных злокачественных новообразований молочной железы // Ранняя диагностика и причины запущенности опухолей основных локализаций. Саратов: Изд-во Сарат. мед. ун-та. 2008. С. 84–93.</mixed-citation><mixed-citation xml:lang="en">Selezneva T.D. Early diagnosis and reasons for the neglect of basic localization of tumors. Saratov, Saratov Med. University Publ., 2008, pp. 84–93 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Бит-Сава Е.М., Белогурова М.Б. Наследственный рак молочной железы // Сиб. онкол. журн. 2013. № 1. С. 75–81.</mixed-citation><mixed-citation xml:lang="en">Bit-Sava E. M., Belogurova M.B. Sibirskiy onko-logicheskiy zhurnal – Siberian Journal of Oncology, 2013, no. 1, pp. 75–81 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Eliassen A.H., Hankinson S.E., Rosner B. et al. Physical activity and risk of breast cancer among postmenopausal women // Arch. Intern. Med. 2010. Vl. 170 (19). Р. 1758–1764.</mixed-citation><mixed-citation xml:lang="en">Eliassen A.H., Hankinson S.E., Rosner B. et al. Physical activity and risk of breast cancer among postmenopausal women. Arch. Intern. Med., 2010, vol. 170 (19), pp. 1758–1764.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Любченко Л.Н., Гаръкавцева Р.Ф., Портной С.М. и др. Предрасположенность к раку молочной железы: этиология и клинические особенности // Мед. генет. 2007. № 6. C. 3–8.</mixed-citation><mixed-citation xml:lang="en">Lyubchenko L.N., Garkavtseva R.F., Portnoy S.M. et al. Medical genetics, 2007, no. 6, pp. 3–8 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Carmichael A., Bendall S., Lockerbie L. et al. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours // EJSO. 2009. V. 28, pp. 388–391.</mixed-citation><mixed-citation xml:lang="en">Carmichael A., Bendall S., Lockerbie L. et al. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. EJSO, 2009, vol. 28, pp. 388–391.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Vichapat V., Gillett C., Fentiman I.S. et al. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways // Eur. J. Cancer. 2011. V. 47. Р. 1919–1927.</mixed-citation><mixed-citation xml:lang="en">Vichapat V., Gillett C., Fentiman I.S. et al. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur. J. Cancer, 2011, vol. 47, pp. 1919–1927.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy J.A., Milner T.D., O'Donoghue J.M. Contralateral risk-reducing mastectomy in sporadic breast cancer // Lan-cet Oncol. 2013. V. 14, pp. 262–269.</mixed-citation><mixed-citation xml:lang="en">Murphy J.A., Milner T.D., O'Donoghue J.M. Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol., 2013, vol. 14, pp. 262–269.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Takahashi H., Watanabe K., Takahashi M. et al. The im-pact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer // Breast Cancer. 2005. V. 12. Р. 196–202.</mixed-citation><mixed-citation xml:lang="en">Takahashi H., Watanabe K., Takahashi M. et al. The im-pact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer, 2005, vol. 12, pp. 196–202.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Boyd N.F., Martin L.J., Yaffe M.J., Minkin S. Mammographic density and breast cancer risk: current understand¬ding and future prospects // Breast Cancer Res. 2011. V. 13, pp. 223.</mixed-citation><mixed-citation xml:lang="en">Boyd N.F., Martin L.J., Yaffe M.J., Minkin S. Mammo-graphic density and breast cancer risk: current understand-ing and future prospects. Breast Cancer Res., 2011, vol. 13, pp. 223.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson D.E. Genetic study of breast cancer: identification of high risk group // Cancer. 1974. V. 34. Р. 1090–1097.</mixed-citation><mixed-citation xml:lang="en">Anderson D.E. Genetic study of breast cancer: identification of high risk group. Cancer, 1974, vol. 34, pp. 1090–1097.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ермилова В.Д. Роль современной патоморфологии в характеристике рака молочной железы // Практическая онкология. 2002. Т. 3, № 1. С. 15–20.</mixed-citation><mixed-citation xml:lang="en">Ermilova V.D. Practical Oncology, 2002, vol. 3, no. 1, рр. 15–20 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fasching P.A., Heusinger K., Loehberg C. et al. Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself // The Breast. 2005. V. 14 (1), pp. 19.</mixed-citation><mixed-citation xml:lang="en">Fasching P.A., Heusinger K., Loehberg C.et al. Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself. The Breast., 2005, vol. 14 (1), p. 19.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Перельмутер В.М., Завьялова М.В., Вторушин С.В., Слонимская Е.М., Савенкова О.В. Взаимосвязь морфологической гетерогенности инфильтрирующего протокового рака молочной железы с различными формами опухолевой прогрессии // Сиб. онкол. журн. 2007. № 3 (23). С. 58–63.</mixed-citation><mixed-citation xml:lang="en">Perelmuter V.M., Zavyalova M.V., Vtorushin S.V., Slonimskaya E.M., Savenkova O.V. Siberian Journal of Oncology, 2007, no. 3, pp. 58–63 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Семиглазов В.Ф., Семиглазов В.В., Воскресенский Д.А. и др. Патоморфология предрака, неинвазивных и инвазивных форм рака молочной железы // Материалы четвертой междунар. ежегод. конф. «Проблемы диагностики и лечения рака молочной железы». СПб. 2007. С. 102–110.</mixed-citation><mixed-citation xml:lang="en">Semiglazov V.F., Semiglazov V.V., Voskresenskiy D.A. et al. Pathomorphology precancer, non-invasive and invasive breast cancer. Proceedings of the fourth annual international conference “Problems of diagnosis and treatment of breast cancer”. St. Petersburg, 2007, pp. 102–110 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Saltzman B.S., Malone K.E., McDougall J.A., Daling J.R., Li C.I. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer // Breast Cancer Res. Treat. 2012. V. 135, pp. 849–855.</mixed-citation><mixed-citation xml:lang="en">Saltzman B.S., Malone K.E., McDougall J.A., Daling J.R., Li C.I. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res. Treat., 2012, vol. 135, pp. 849–855.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kurian A.W. et al. Second primary breast cancer occur-rence according to hormone receptor status // J. Natl. Can-cer Inst. 2009. V. 101, pp. 1058–1065.</mixed-citation><mixed-citation xml:lang="en">Kurian A.W. et al. Second primary breast cancer occur-rence according to hormone receptor status. J. Natl. Cancer Inst., 2009, vol. 101, pp. 1058–1065.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Bessonova L., Taylor T.H., Mehta R.S., Zell J.A., Anton-Culver H. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer // Cancer Epidemiol. Biomarkers Prev. 2011. V. 20, pp. 389–396.</mixed-citation><mixed-citation xml:lang="en">Bessonova L., Taylor T.H., Mehta R.S., Zell J.A., Anton-Culver H. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol. Biomarkers Prev., 2011, vol. 20, pp. 389–396.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kollias J., Pinder S.E., Denley H.E. et al. Phenotypic simi-larities in bilateral breast cancer // Breast Cancer Res. Treat. 2004. V. 85. Р. 255–261.</mixed-citation><mixed-citation xml:lang="en">Kollias J., Pinder S.E., Denley H.E. et al. Phenotypic simi-larities in bilateral breast cancer. Breast Cancer Res. Treat., 2004, vol. 85, pp. 255–261.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer // N. Engl. J. Med. 2009. V. 360 (8). Р. 790–800.</mixed-citation><mixed-citation xml:lang="en">Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med., 2009, vol. 360(8). Р. 790–800.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Swain S.M., Wilson J.W., Mamounas E.P. et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer // J. Natl. Cancer Inst. 2004. V. 96. Р. 516–523.</mixed-citation><mixed-citation xml:lang="en">Swain S.M., Wilson J.W., Mamounas E.P. et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J. Natl. Cancer Inst., 2004, vol. 96, pp. 516–523.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Metcalfe K. et al. Predictors of contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers // Br. J. Can-cer. 2011. V. 104, pp. 1384–1392.</mixed-citation><mixed-citation xml:lang="en">Metcalfe K. et al. Predictors of contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer, 2011, vol. 104, pp. 1384–1392.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Голубев О.А., Абросимов С.Ю., Шистерова О.А. Морфометрические и иммуногистохимические маркеры прогрессии рака молочной железы // Архив патологии. 2001. № 4. С. 57–60.</mixed-citation><mixed-citation xml:lang="en">Golubev O.A., Abrosimov S.Yu., Shisterova O.A. Arkhiv patologii – Archive of Pathology, 2001, no. 4, pp. 57–60 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Delpech Y., Wu Y., Hess K.R., Hsu L., Ayers M. et al. Ki67 expression in the primary tumor predicts for clinical bene-fit and time to progression on first-line endocrine the¬rapy in estrogen receptor-positive metastatic breast cancer // Breast Cancer Res. Treat. 2012. V. 135 (2). Р. 619–627.</mixed-citation><mixed-citation xml:lang="en">Delpech Y., Wu Y., Hess K.R., Hsu L., Ayers M. et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res. Treat., 2012, vol. 135 (2), pp. 619–627.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Lacroix M., Toillon R.A., Leclercq G. p53 and breast can-cer, an update // Endocrine-related Cancer. 2006. V. 13 (2). Р. 293–325.</mixed-citation><mixed-citation xml:lang="en">Lacroix M., Toillon R.A., Leclercq G. p53 and breast can-cer, an update. Endocrine-related Cancer, 2006, vol. 13 (2), pp. 293–325.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Поддубная И.В., Карселадзе Д.А. «Тройной негатив-ный» рак молочной железы // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. Т. 20, № 3. С. 12–19.</mixed-citation><mixed-citation xml:lang="en">Poddubnaya I.V., Karseladze D.A. Vestnik Rossiyskogo onkologicheskogo nauchnogo tsentra imeni N.N. Blokhina RAMN – Herald of N.N. Blokhin Cancer Research Center, RAMS, 2009, vol. 20, no. 3, pp. 12–19.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer // Clin. Breast. Cancer. 2009. Suppl. 2, pp. 73–81.</mixed-citation><mixed-citation xml:lang="en">Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast. Cancer, 2009. Suppl. 2, pp. 73–81.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Dragun A.E., Pan J. et al. Locoregional recurrence in pa-tients with triple-negative breast cancer: preliminary results of a single institution study // Am. J. Clin. Oncol. 2011. V. 34 (3), pp. 231–237.</mixed-citation><mixed-citation xml:lang="en">Dragun A.E., Pan J. et al. Locoregional recurrence in pa-tients with triple-negative breast cancer: preliminary results of a single institution study. Am. J. Clin. Oncol., 2011, vol. 34 (3), pp. 231–237.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Weigelt B., Peterse J.L., Van't Veer L.J. Breast cancer metastasis: marcers and models // Nature Publishing Group. 2005. V. 5, pp. 591–602.</mixed-citation><mixed-citation xml:lang="en">Weigelt B., Peterse J.L., Van't Veer L.J. Breast cancer me-tastasis: marcers and models. Nature Publishing Group., 2005, vol. 5, pp. 591–602.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Huston T.L., Pressman P.I., Moore A. et al. The presenta-tion of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma // Breast Journal. 2007. V. 2. Р. 158–164.</mixed-citation><mixed-citation xml:lang="en">Huston T.L., Pressman P.I., Moore A. et al. The presenta-tion of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma. Breast Journal, 2007, vol. 2. Р. 158–164.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Вторушин С.В., Завьялова М.В. Зависимость лимфогенного метастазирования инфильтрирующего протокового рака молочной железы от гистологического строения опухоли у больных, не получавших предоперационной терапии // Cб. «Науки о человеке»: материалы VIII конгр. молодых ученых и специалистов / под ред. Л.М. Огородовой, Л.В. Ка-пилевича. Томск: СибГМУ, 2007. 273 с.</mixed-citation><mixed-citation xml:lang="en">Vtorushin S.V., Zavyalova M.V. Dependence of nodal metastasis of infiltrating ductal breast cancer on the histological structure of the tumor in patients who did not receive preoperative therapy. Proceedings of the VIII Congress of Young Scientists and Specialists “Science of Man”. Tomsk, 2007. 273 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Завьялова М.В. Взаимосвязь морфологического фенотипа опухоли, лимфогенного и гематогенного метастазирования при инфильтрирующем протоковом раке молочной железы: автореф. дис. … д-ра мед. наук. Томск, 2009. 41 с.</mixed-citation><mixed-citation xml:lang="en">Zavyalova M.V. Relationship morphological phenotype of the tumor, lymphatic and hematogenous metastasis in infiltrating ductal carcinoma of the breast. Author. dis. Dr. med. sci. Tomsk, 2009. 41 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Bonin S., Brunetti D., Benedetti E. Molecular characteriza-tion of breast cancer patients at high and low recurrence risk // Vichows Arch. 2008. V. 52 (3). Р. 241–250.</mixed-citation><mixed-citation xml:lang="en">Bonin S., Brunetti D., Benedetti E. Molecular characteriza-tion of breast cancer patients at high and low recurrence risk. Vichows Arch., 2008, vol. 52(3). Р. 241–250.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Schmid S.M., Pfefferkorn C., Myrick M.E. et al. Prognosis of early-stage synchronous bilateral invasive breast cancer // EJSO. 2011. V. 37, iss. 7, pp. 623–628.</mixed-citation><mixed-citation xml:lang="en">Schmid S.M., Pfefferkorn C., Myrick M.E. et al. Prognosis of early-stage synchronous bilateral invasive breast cancer. EJSO, 2011, vol. 37, iss. 7, pp. 623–628.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Beckmann K.R., Buckingham J., Craft P. et al. Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort // The Breast. 2011. V. 20, iss. 2, pp. 158–164.</mixed-citation><mixed-citation xml:lang="en">Beckmann K.R., Buckingham J., Craft P. et al. Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort. The Breast, 2011, vol. 20, iss. 2, pp. 158–164.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Hartman M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer // J. Clin. Oncol. 2007. V. 25, pp. 4210–4216.</mixed-citation><mixed-citation xml:lang="en">Hartman M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J. Clin. Oncol., 2007, vol. 25, pp. 4210–4216.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Fodor J. Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence // Magy Oncol. 2007. V. 51 (2), pp. 127–131.</mixed-citation><mixed-citation xml:lang="en">Fodor J. Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence. Magy Oncol., 2007, vol. 51(2), pp. 127–131.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen P.L., Taghian A.G., Katz M.S. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy // J. Clin. Oncol. 2008. V. 10, iss. 26 (14), pp. 2373–2378.</mixed-citation><mixed-citation xml:lang="en">Nguyen P.L., Taghian A.G., Katz M.S. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol., 2008, vol. 10, iss. 26 (14), pp. 2373–2378.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Garami Z., Szluha K., Fulop B. et al. Significance of the intraductal component in local recurrence after breast-conserving surgery // Magy Seb. 2008. V. 61 (1). Р. 12–17.</mixed-citation><mixed-citation xml:lang="en">Garami Z., Szluha K., Fulop B. et al. Significance of the intraductal component in local recurrence after breast-conserving surgery. Magy Seb., 2008, vol. 61(1), pp. 12–17.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Bhandari T., Dizon D.S., Taneja C. et al. Clinical characteristics of women presenting with skin-only recur-rence of breast cancer // Am. J. Surg. 2007. V. 194 (4), pp. 494–496.</mixed-citation><mixed-citation xml:lang="en">Bhandari T., Dizon D.S., Taneja C. et al Clinical characteristics of women presenting with skin-only recurrence of breast cancer. Am. J. Surg., 2007, vol. 194(4), pp. 494–496.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Boehm D.U., Lebrecht A., Maltaris T. et al. Influence of resection volume on locoregional recurrence of breast cancer after breast-conserving surgery // Anticancer Res. 2008. V. 28 (2B). Р. 1207–1211.</mixed-citation><mixed-citation xml:lang="en">Boehm D.U., Lebrecht A., Maltaris T. et al. Influence of resection volume on locoregional recurrence of breast cancer after breast-conserving surgery. Anticancer Res., 2008, vol. 28 (2B), pp. 1207–1211.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Phillips K.A. et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. 2013. V. 31, pp. 3091–3099.</mixed-citation><mixed-citation xml:lang="en">Phillips K.A. et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol., 2013, vol. 31, pp. 3091–3099.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Казатова Ю.Д. Диагностика и лечение рецидивов рака молочной железы: автореф. дис. … кандидат медицинских наук. Бишкек, 2005. 64 с.</mixed-citation><mixed-citation xml:lang="en">Kazatova Yu.D. Diagnosis and treatment of breast cancer recurrence. Author. dis. cand. med. sci. Bishkek, 2005. 64 p. (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Jaffre F., Lavoue V., Mesbah H. et al. Prognosis for isolated skin recurrence after breast cancer treated by mastectomy // Anticancer Res. 2009. V. 29 (5), pp. 1697–1701.</mixed-citation><mixed-citation xml:lang="en">Jaffre F., Lavoue V., Mesbah H. et al. Prognosis for isolated skin recurrence after breast cancer treated by mastectomy. Anticancer Res., 2009, vol. 29 (5), pp. 1697–1701.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Вторушин С.В., Перельмутер В.М., Завьялова М.В., Слонимская Е.М. Синхронное и метахронное развитие локальных рецидивов и отдаленных метастазов у боль-ных раком молочной железы // Сиб. онкол. журн. 2011. № 2 (44). С. 27–32.</mixed-citation><mixed-citation xml:lang="en">Vtorushin S.V., Perelmuter V.M., Zavyalova M.V., Slonimskaya E.M. Sibirskiy onkologicheskiy zhurnal – Siberian Journal of Oncology, 2011, no. 2, pp. 27–32 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Bebson J.R., della Rovere G.Q. Ipsilateral breast cancer re-currence // Breast. 2008. V. 17 (1). Р. 12–18.</mixed-citation><mixed-citation xml:lang="en">Bebson J.R., della Rovere G.Q. Ipsilateral breast cancer re-currence. Breast, 2008, vol. 17(1), pp. 12–18.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Li C.I., Daling J.R., Porter P.L., Tang M.T., Malone K.E. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer // Cancer Res. 2009. V. 69. Р. 6865–6870.</mixed-citation><mixed-citation xml:lang="en">Li C.I., Daling J.R., Porter P.L., Tang M.T., Malone K.E. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res., 2009, vol. 69, pp. 6865–6870.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
